Pharmaceutical

Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.

Aug 18, 2023 - 20:00
Imugene licenses potential first-to-market allogeneic CAR T for blood cancers
Imugene's azercabtagene zarpreleucel (azer-cel) allo-CAR T cell therapy has shown a 58% ORR and 41% CR rate across all doses.
Read the original article

Tags:

Previous Article

Boehringer Ingelheim advances weight loss drug to Phase III trials

Next Article

Signal: Abortion pill restriction may drive more patients to off-label drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Inline, real-time PAT tool is a game-changer for pharma granulation sector

Inline, real-time PAT tool is a game-changer for pharma...

Jun 4, 2024

Keytruda remains Merck & Co’s biggest 2023 success story as patent expiry looms

Keytruda remains Merck & Co’s biggest 2023 success stor...

Feb 2, 2024

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

Oct 25, 2023